| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 38 | 2018 | 357 | 5.250 |
Why?
|
| Myeloproliferative Disorders | 19 | 2016 | 132 | 3.360 |
Why?
|
| Leukemia, Myeloid, Acute | 33 | 2018 | 788 | 2.050 |
Why?
|
| World Health Organization | 20 | 2016 | 106 | 2.030 |
Why?
|
| Bone Marrow | 48 | 2018 | 445 | 1.970 |
Why?
|
| Chromosome Aberrations | 39 | 2012 | 390 | 1.670 |
Why?
|
| Leukemia | 20 | 2017 | 323 | 1.420 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 10 | 2009 | 173 | 1.300 |
Why?
|
| Leukemia, Myeloid | 25 | 2016 | 249 | 1.140 |
Why?
|
| Leukemia, Hairy Cell | 31 | 1994 | 186 | 1.130 |
Why?
|
| Primary Myelofibrosis | 13 | 2010 | 67 | 1.090 |
Why?
|
| Lymphoma | 14 | 2009 | 265 | 1.030 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2009 | 108 | 0.760 |
Why?
|
| Polycythemia Vera | 7 | 2009 | 23 | 0.680 |
Why?
|
| Thrombocythemia, Essential | 6 | 2009 | 14 | 0.640 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 88 | 0.630 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 93 | 0.600 |
Why?
|
| Humans | 188 | 2019 | 89063 | 0.580 |
Why?
|
| Azacitidine | 1 | 2018 | 146 | 0.580 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2018 | 665 | 0.580 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 34 | 0.560 |
Why?
|
| Trans-Activators | 3 | 2018 | 443 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 616 | 0.510 |
Why?
|
| Translocation, Genetic | 21 | 2014 | 266 | 0.490 |
Why?
|
| Acute Disease | 26 | 2017 | 841 | 0.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 1999 | 261 | 0.460 |
Why?
|
| Blood Cells | 4 | 2012 | 33 | 0.450 |
Why?
|
| Hypergammaglobulinemia | 1 | 2013 | 8 | 0.450 |
Why?
|
| Erythropoiesis | 4 | 2011 | 51 | 0.440 |
Why?
|
| Histiocytosis, Sinus | 1 | 2013 | 15 | 0.440 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 2411 | 0.440 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 2 | 2009 | 10 | 0.430 |
Why?
|
| Plasma Cells | 1 | 2013 | 84 | 0.420 |
Why?
|
| Hodgkin Disease | 6 | 1998 | 181 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2012 | 395 | 0.390 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 463 | 0.380 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 18 | 0.370 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 249 | 0.370 |
Why?
|
| Histones | 1 | 2013 | 329 | 0.370 |
Why?
|
| Prognosis | 34 | 2014 | 3773 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 8 | 6 | 2004 | 85 | 0.360 |
Why?
|
| Male | 102 | 2015 | 42251 | 0.360 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 306 | 0.350 |
Why?
|
| Karyotyping | 36 | 2006 | 253 | 0.340 |
Why?
|
| Mutation | 10 | 2009 | 4132 | 0.340 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 506 | 0.330 |
Why?
|
| Middle Aged | 85 | 2019 | 25863 | 0.320 |
Why?
|
| Female | 96 | 2019 | 46011 | 0.320 |
Why?
|
| Genome, Human | 2 | 2013 | 767 | 0.320 |
Why?
|
| Chromosome Disorders | 11 | 1995 | 115 | 0.320 |
Why?
|
| Aged | 71 | 2014 | 19077 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2014 | 2552 | 0.310 |
Why?
|
| Diagnosis, Differential | 12 | 2009 | 1591 | 0.310 |
Why?
|
| Lymphoproliferative Disorders | 6 | 2000 | 111 | 0.300 |
Why?
|
| Cytarabine | 10 | 2012 | 219 | 0.300 |
Why?
|
| Hematologic Neoplasms | 7 | 2015 | 342 | 0.300 |
Why?
|
| Adult | 89 | 2014 | 26507 | 0.300 |
Why?
|
| Blast Crisis | 4 | 2008 | 36 | 0.290 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 540 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 21 | 6 | 2004 | 54 | 0.270 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2003 | 157 | 0.260 |
Why?
|
| Interferon Type I | 10 | 1992 | 178 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 5 | 5 | 2009 | 109 | 0.250 |
Why?
|
| Methylation | 2 | 2018 | 268 | 0.240 |
Why?
|
| Terminology as Topic | 3 | 2012 | 221 | 0.230 |
Why?
|
| Algorithms | 4 | 2009 | 1875 | 0.230 |
Why?
|
| Burkitt Lymphoma | 3 | 2004 | 32 | 0.230 |
Why?
|
| Trisomy | 6 | 2002 | 55 | 0.220 |
Why?
|
| Guidelines as Topic | 3 | 2012 | 160 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2016 | 133 | 0.210 |
Why?
|
| Adolescent | 29 | 2014 | 9237 | 0.210 |
Why?
|
| Daunorubicin | 7 | 2012 | 78 | 0.210 |
Why?
|
| Interferon-alpha | 5 | 1994 | 226 | 0.200 |
Why?
|
| Lymphatic Diseases | 3 | 2013 | 36 | 0.200 |
Why?
|
| Antigens, Neoplasm | 5 | 1990 | 332 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 2 | 2009 | 161 | 0.190 |
Why?
|
| Aged, 80 and over | 19 | 2014 | 6777 | 0.180 |
Why?
|
| Survival Analysis | 12 | 2008 | 1533 | 0.180 |
Why?
|
| Chromosomes, Human, 16-18 | 7 | 1984 | 26 | 0.180 |
Why?
|
| Cell Lineage | 5 | 2016 | 291 | 0.180 |
Why?
|
| Composite Lymphoma | 1 | 2019 | 2 | 0.170 |
Why?
|
| Chromosome Inversion | 6 | 2014 | 47 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 3 | 2003 | 260 | 0.170 |
Why?
|
| Chromosome Deletion | 10 | 2009 | 229 | 0.170 |
Why?
|
| Lymph Nodes | 10 | 2013 | 548 | 0.170 |
Why?
|
| Classification | 3 | 2006 | 54 | 0.170 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2018 | 76 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 283 | 0.160 |
Why?
|
| Mastocytosis | 3 | 2016 | 13 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 1995 | 103 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2008 | 80 | 0.160 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 3 | 0.160 |
Why?
|
| Histiocytes | 2 | 1998 | 22 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 6 | 0.160 |
Why?
|
| GATA1 Transcription Factor | 1 | 2018 | 18 | 0.160 |
Why?
|
| Child, Preschool | 9 | 2013 | 3717 | 0.150 |
Why?
|
| Etoposide | 6 | 2010 | 198 | 0.150 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 60 | 0.150 |
Why?
|
| Hematopoiesis | 5 | 2015 | 165 | 0.150 |
Why?
|
| Antigens, Differentiation | 4 | 1991 | 141 | 0.150 |
Why?
|
| Remission Induction | 12 | 2012 | 740 | 0.150 |
Why?
|
| Bone Marrow Examination | 6 | 2009 | 47 | 0.140 |
Why?
|
| Cytosine | 1 | 2018 | 128 | 0.140 |
Why?
|
| Infant | 3 | 2013 | 3147 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2008 | 354 | 0.140 |
Why?
|
| Hematopoietic System | 3 | 2009 | 13 | 0.140 |
Why?
|
| Methyltransferases | 1 | 2018 | 192 | 0.140 |
Why?
|
| Anemia | 3 | 2009 | 129 | 0.140 |
Why?
|
| Spleen | 7 | 2001 | 432 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2014 | 889 | 0.140 |
Why?
|
| Philadelphia Chromosome | 1 | 1996 | 41 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2009 | 1543 | 0.130 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 5 | 0.130 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 557 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1993 | 112 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 22 | 4 | 2004 | 44 | 0.130 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1995 | 7 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 401 | 0.130 |
Why?
|
| Transcription Factors | 3 | 2018 | 1652 | 0.130 |
Why?
|
| Eosinophilia | 3 | 2016 | 84 | 0.130 |
Why?
|
| Chromatin | 1 | 2018 | 397 | 0.120 |
Why?
|
| Preleukemia | 2 | 2009 | 11 | 0.120 |
Why?
|
| Child | 13 | 2013 | 7149 | 0.120 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2014 | 9 | 0.120 |
Why?
|
| Chromosomes, Human, 6-12 and X | 6 | 1986 | 23 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 579 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 204 | 0.120 |
Why?
|
| Abnormal Karyotype | 1 | 2014 | 8 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 1998 | 275 | 0.120 |
Why?
|
| Protein Binding | 1 | 2018 | 1487 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 29 | 0.120 |
Why?
|
| Splenectomy | 7 | 1988 | 82 | 0.120 |
Why?
|
| Bone Marrow Cells | 7 | 2015 | 262 | 0.110 |
Why?
|
| Alkaline Phosphatase | 5 | 1988 | 132 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.110 |
Why?
|
| Leukocyte Count | 10 | 2015 | 223 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 100 | 0.110 |
Why?
|
| Methotrexate | 2 | 2012 | 250 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2008 | 299 | 0.110 |
Why?
|
| Gene Expression Profiling | 4 | 2014 | 1429 | 0.110 |
Why?
|
| Megakaryocytes | 4 | 2008 | 36 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2012 | 447 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 726 | 0.110 |
Why?
|
| Sclerosis | 1 | 2013 | 29 | 0.110 |
Why?
|
| T-Lymphocytes | 6 | 2014 | 1223 | 0.110 |
Why?
|
| Cyclosporins | 2 | 2010 | 58 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 136 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2004 | 86 | 0.110 |
Why?
|
| Mastocytosis, Systemic | 2 | 2009 | 12 | 0.100 |
Why?
|
| Vidarabine | 2 | 2003 | 143 | 0.100 |
Why?
|
| Anemia, Refractory | 3 | 1996 | 5 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2004 | 85 | 0.100 |
Why?
|
| Janus Kinase 2 | 2 | 2009 | 60 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2552 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2013 | 691 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 282 | 0.100 |
Why?
|
| fas Receptor | 1 | 2012 | 77 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2005 | 299 | 0.100 |
Why?
|
| Splenomegaly | 3 | 2004 | 28 | 0.100 |
Why?
|
| Neutropenia | 3 | 2007 | 216 | 0.100 |
Why?
|
| Erythropoietin | 3 | 1997 | 88 | 0.100 |
Why?
|
| Recombinant Proteins | 11 | 1996 | 1012 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1997 | 166 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 270 | 0.090 |
Why?
|
| Follow-Up Studies | 13 | 2014 | 3657 | 0.090 |
Why?
|
| Biopsy | 8 | 2014 | 1182 | 0.090 |
Why?
|
| Leukemia, Monocytic, Acute | 3 | 1987 | 14 | 0.090 |
Why?
|
| Treatment Outcome | 15 | 2010 | 8203 | 0.090 |
Why?
|
| Survival Rate | 6 | 2012 | 1889 | 0.090 |
Why?
|
| Interferons | 3 | 1990 | 124 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1855 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 12 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 1241 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 27 | 0.090 |
Why?
|
| Hematinics | 1 | 2009 | 11 | 0.090 |
Why?
|
| Eosinophils | 3 | 1986 | 194 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 1837 | 0.090 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 57 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2001 | 79 | 0.090 |
Why?
|
| Gene Expression | 2 | 2009 | 1310 | 0.080 |
Why?
|
| Thalidomide | 1 | 2009 | 57 | 0.080 |
Why?
|
| Topotecan | 1 | 2009 | 45 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 200 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 2 | 1987 | 133 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 307 | 0.080 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2012 | 85 | 0.080 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2008 | 9 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 97 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 1988 | 306 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1985 | 114 | 0.080 |
Why?
|
| Chlorambucil | 2 | 1984 | 23 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 556 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2011 | 0.080 |
Why?
|
| Drug Administration Schedule | 7 | 2009 | 894 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 1992 | 30 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2007 | 5 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2007 | 36 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2006 | 1043 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2018 | 3373 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 5 | 1992 | 72 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2012 | 1214 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2362 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 551 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2014 | 54 | 0.070 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 101 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 73 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 148 | 0.070 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2006 | 1 | 0.070 |
Why?
|
| Thrombocytosis | 2 | 1996 | 8 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2007 | 948 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2004 | 79 | 0.070 |
Why?
|
| Bone Marrow Diseases | 4 | 2015 | 40 | 0.060 |
Why?
|
| Cisplatin | 1 | 1987 | 617 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 657 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2002 | 106 | 0.060 |
Why?
|
| Lung Neoplasms | 4 | 1987 | 2347 | 0.060 |
Why?
|
| Mice | 5 | 2015 | 11737 | 0.060 |
Why?
|
| Neutrophils | 6 | 1997 | 308 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1796 | 0.060 |
Why?
|
| Cladribine | 1 | 2003 | 35 | 0.050 |
Why?
|
| Fibrosis | 2 | 1996 | 234 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2002 | 51 | 0.050 |
Why?
|
| Skin Diseases | 1 | 1984 | 173 | 0.050 |
Why?
|
| Europe | 2 | 2001 | 321 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2012 | 1710 | 0.050 |
Why?
|
| Leukemia, B-Cell | 1 | 2002 | 23 | 0.050 |
Why?
|
| Base Sequence | 4 | 2012 | 2327 | 0.050 |
Why?
|
| Chromosomes, Human, 13-15 | 4 | 1985 | 32 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1982 | 23 | 0.050 |
Why?
|
| Retrospective Studies | 11 | 2008 | 9003 | 0.050 |
Why?
|
| Anemia, Aplastic | 3 | 2015 | 32 | 0.050 |
Why?
|
| Staining and Labeling | 6 | 2001 | 168 | 0.050 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1981 | 30 | 0.050 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 26 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 2399 | 0.050 |
Why?
|
| Liver | 5 | 1989 | 1205 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2001 | 126 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1998 | 154 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1992 | 65 | 0.050 |
Why?
|
| Antigens, CD | 3 | 1991 | 466 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 161 | 0.040 |
Why?
|
| Phenotype | 3 | 2015 | 2439 | 0.040 |
Why?
|
| Ki-1 Antigen | 2 | 1990 | 19 | 0.040 |
Why?
|
| Hepatitis C | 1 | 1982 | 170 | 0.040 |
Why?
|
| Disease Progression | 3 | 2006 | 1488 | 0.040 |
Why?
|
| Lymphocytes | 4 | 1995 | 471 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2001 | 67 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 1996 | 8 | 0.040 |
Why?
|
| International Cooperation | 1 | 2000 | 125 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 2014 | 0.040 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 1998 | 23 | 0.040 |
Why?
|
| Time Factors | 7 | 2003 | 5320 | 0.040 |
Why?
|
| Animals | 5 | 2015 | 27317 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2006 | 988 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2009 | 4273 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1998 | 112 | 0.040 |
Why?
|
| Platelet Count | 3 | 1989 | 93 | 0.040 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 3 | 1985 | 14 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 4 | 2002 | 1400 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 887 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 1994 | 129 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 1995 | 217 | 0.040 |
Why?
|
| Gene Deletion | 1 | 1998 | 342 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 37 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 1715 | 0.030 |
Why?
|
| Age Factors | 3 | 2008 | 1867 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 1996 | 7 | 0.030 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 159 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 14 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2016 | 55 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2015 | 23 | 0.030 |
Why?
|
| Young Adult | 3 | 2014 | 6288 | 0.030 |
Why?
|
| Chromosomes, Human, 19-20 | 3 | 1986 | 5 | 0.030 |
Why?
|
| Drug Therapy, Combination | 5 | 1997 | 783 | 0.030 |
Why?
|
| Chromosome Banding | 6 | 1991 | 74 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 100 | 0.030 |
Why?
|
| Leukemia, Mast-Cell | 2 | 2008 | 5 | 0.030 |
Why?
|
| Aziridines | 2 | 2005 | 9 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 80 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 54 | 0.030 |
Why?
|
| Benzoquinones | 2 | 2005 | 27 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 1994 | 921 | 0.030 |
Why?
|
| Mitoxantrone | 2 | 2005 | 68 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 3027 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1994 | 16 | 0.030 |
Why?
|
| Cytogenetic Analysis | 2 | 2006 | 71 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1991 | 20 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1994 | 20 | 0.030 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 15 | 0.030 |
Why?
|
| Splenic Neoplasms | 1 | 1994 | 17 | 0.030 |
Why?
|
| Decision Making | 1 | 2000 | 665 | 0.030 |
Why?
|
| Chromosomes, Human, 4-5 | 2 | 1986 | 10 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2014 | 83 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 127 | 0.030 |
Why?
|
| Acid Phosphatase | 4 | 1988 | 34 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2007 | 529 | 0.030 |
Why?
|
| HTLV-I Infections | 1 | 1993 | 7 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1993 | 14 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 1265 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1994 | 251 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 84 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1994 | 106 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 1992 | 31 | 0.030 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2004 | 57 | 0.030 |
Why?
|
| Digestive System | 2 | 1984 | 42 | 0.030 |
Why?
|
| Incidence | 2 | 1994 | 1592 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2003 | 434 | 0.030 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2012 | 20 | 0.030 |
Why?
|
| Gene Rearrangement | 2 | 1990 | 172 | 0.030 |
Why?
|
| Animal Diseases | 1 | 1992 | 4 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 866 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2012 | 72 | 0.020 |
Why?
|
| Cell Division | 2 | 1990 | 696 | 0.020 |
Why?
|
| Neoplasms | 3 | 2004 | 3035 | 0.020 |
Why?
|
| Blood Cell Count | 4 | 1987 | 79 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2014 | 599 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 159 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1990 | 17 | 0.020 |
Why?
|
| Recurrence | 2 | 2004 | 1140 | 0.020 |
Why?
|
| Lymphocytosis | 1 | 1990 | 12 | 0.020 |
Why?
|
| Animals, Zoo | 1 | 1992 | 68 | 0.020 |
Why?
|
| Heterozygote | 1 | 1992 | 373 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1990 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1991 | 125 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1990 | 49 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1984 | 130 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1990 | 71 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 258 | 0.020 |
Why?
|
| Basophils | 2 | 1985 | 26 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1990 | 202 | 0.020 |
Why?
|
| Risk Factors | 3 | 2004 | 5466 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1990 | 394 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1988 | 233 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2005 | 848 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 1985 | 96 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 171 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 205 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1108 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2008 | 157 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 1983 | 510 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 316 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1994 | 2863 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 103 | 0.020 |
Why?
|
| Cytogenetics | 2 | 1991 | 27 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 682 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1991 | 1363 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2009 | 357 | 0.020 |
Why?
|
| United States | 1 | 2000 | 6955 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1992 | 243 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2008 | 210 | 0.020 |
Why?
|
| Interphase | 3 | 1991 | 35 | 0.020 |
Why?
|
| Kidney | 2 | 1984 | 1145 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2880 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 2000 | 330 | 0.020 |
Why?
|
| Cat-Scratch Disease | 1 | 1986 | 1 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1986 | 15 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2003 | 2001 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1986 | 35 | 0.020 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1986 | 27 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2003 | 865 | 0.020 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2005 | 17 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 35 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1985 | 42 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1989 | 1076 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 698 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 1130 | 0.020 |
Why?
|
| Binding Sites | 1 | 2008 | 1117 | 0.020 |
Why?
|
| Random Allocation | 2 | 1987 | 328 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 315 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1716 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1714 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 371 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 20 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 306 | 0.020 |
Why?
|
| Phagocytosis | 3 | 1980 | 86 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3209 | 0.020 |
Why?
|
| Leukopenia | 1 | 1984 | 66 | 0.020 |
Why?
|
| Lymphokines | 1 | 1984 | 76 | 0.020 |
Why?
|
| Autopsy | 1 | 1984 | 122 | 0.020 |
Why?
|
| Aneuploidy | 2 | 1981 | 57 | 0.010 |
Why?
|
| Osteolysis | 1 | 1984 | 14 | 0.010 |
Why?
|
| Respiratory System | 1 | 1984 | 116 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1984 | 42 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1984 | 60 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 127 | 0.010 |
Why?
|
| Neck | 1 | 1984 | 103 | 0.010 |
Why?
|
| Granulocytes | 1 | 1983 | 38 | 0.010 |
Why?
|
| Hematocrit | 1 | 1983 | 68 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 727 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 237 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 225 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 77 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 244 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1982 | 92 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 478 | 0.010 |
Why?
|
| Organ Size | 1 | 1983 | 369 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 283 | 0.010 |
Why?
|
| Rituximab | 1 | 2002 | 119 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1982 | 56 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2001 | 27 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 343 | 0.010 |
Why?
|
| Tryptases | 1 | 2001 | 12 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 2001 | 7 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 2001 | 22 | 0.010 |
Why?
|
| Viscera | 1 | 2001 | 18 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2001 | 15 | 0.010 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2001 | 8 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 315 | 0.010 |
Why?
|
| Mast Cells | 1 | 2001 | 94 | 0.010 |
Why?
|
| Clone Cells | 1 | 2001 | 214 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 372 | 0.010 |
Why?
|
| North America | 1 | 2001 | 184 | 0.010 |
Why?
|
| Skin | 2 | 2001 | 581 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2001 | 131 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 344 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1212 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 172 | 0.010 |
Why?
|
| Immunologic Capping | 1 | 1980 | 14 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 155 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 645 | 0.010 |
Why?
|
| Syndrome | 1 | 1981 | 449 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 146 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2001 | 153 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 312 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 274 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1991 | 232 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1989 | 138 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 682 | 0.010 |
Why?
|
| Reticulin | 1 | 1978 | 4 | 0.010 |
Why?
|
| Sex Factors | 1 | 1982 | 1063 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1978 | 12 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1940 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 1706 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1981 | 295 | 0.010 |
Why?
|
| B-Lymphocytes | 3 | 1991 | 738 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 1135 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1996 | 27 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 48 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 305 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 138 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 306 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 1975 | 9 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1975 | 0.010 |
Why?
|
| Monosomy | 1 | 1995 | 12 | 0.010 |
Why?
|
| Abdomen | 1 | 1975 | 122 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1975 | 171 | 0.010 |
Why?
|
| Biomarkers | 1 | 2001 | 1755 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1975 | 178 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 66 | 0.010 |
Why?
|
| Brain | 1 | 1984 | 2281 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 2335 | 0.010 |
Why?
|
| Cytoplasmic Granules | 3 | 1980 | 96 | 0.010 |
Why?
|
| Monocytes | 2 | 1985 | 218 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1993 | 202 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1992 | 10 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1993 | 261 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 258 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 543 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1992 | 87 | 0.010 |
Why?
|
| Lung | 1 | 1979 | 1258 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 565 | 0.010 |
Why?
|
| Bufonidae | 1 | 1992 | 2 | 0.010 |
Why?
|
| Hedgehogs | 1 | 1992 | 2 | 0.010 |
Why?
|
| Lions | 1 | 1992 | 2 | 0.010 |
Why?
|
| Snakes | 1 | 1992 | 9 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 147 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1988 | 1149 | 0.010 |
Why?
|
| CD11 Antigens | 1 | 1991 | 15 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1991 | 14 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1991 | 35 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1991 | 111 | 0.010 |
Why?
|
| Pentostatin | 1 | 1990 | 30 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1992 | 243 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 901 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1992 | 331 | 0.010 |
Why?
|
| X Chromosome | 1 | 1991 | 153 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 77 | 0.010 |
Why?
|
| Birds | 1 | 1992 | 165 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1990 | 111 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 1990 | 73 | 0.010 |
Why?
|
| Metaphase | 2 | 1980 | 25 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 1980 | 27 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 268 | 0.010 |
Why?
|
| Centromere | 1 | 1988 | 26 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1989 | 192 | 0.010 |
Why?
|
| Leukocytes | 2 | 1980 | 204 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1986 | 16 | 0.000 |
Why?
|
| Francisella | 1 | 1986 | 1 | 0.000 |
Why?
|
| Haemophilus | 1 | 1986 | 1 | 0.000 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1986 | 10 | 0.000 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1986 | 14 | 0.000 |
Why?
|
| Antitubercular Agents | 1 | 1986 | 54 | 0.000 |
Why?
|
| Erythrocyte Transfusion | 1 | 1986 | 72 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1986 | 166 | 0.000 |
Why?
|
| Mitosis | 2 | 1976 | 152 | 0.000 |
Why?
|
| Lymphopenia | 1 | 1985 | 31 | 0.000 |
Why?
|
| Colony-Stimulating Factors | 1 | 1984 | 14 | 0.000 |
Why?
|
| Immune Sera | 1 | 1984 | 52 | 0.000 |
Why?
|
| Interleukin-3 | 1 | 1984 | 36 | 0.000 |
Why?
|
| Thymidine | 1 | 1984 | 59 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1984 | 53 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 1307 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1984 | 149 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1986 | 160 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1985 | 187 | 0.000 |
Why?
|
| Retroviridae Infections | 1 | 1984 | 48 | 0.000 |
Why?
|
| Mutagens | 1 | 1982 | 31 | 0.000 |
Why?
|
| Insecticides | 1 | 1982 | 27 | 0.000 |
Why?
|
| Solvents | 1 | 1982 | 96 | 0.000 |
Why?
|
| Metals | 1 | 1982 | 93 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1981 | 137 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1981 | 73 | 0.000 |
Why?
|
| Zymosan | 1 | 1980 | 6 | 0.000 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1980 | 14 | 0.000 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 1980 | 6 | 0.000 |
Why?
|
| Tartrates | 1 | 1980 | 6 | 0.000 |
Why?
|
| Lectins | 1 | 1980 | 84 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1980 | 24 | 0.000 |
Why?
|
| Butyrates | 1 | 1980 | 46 | 0.000 |
Why?
|
| Quinacrine | 1 | 1978 | 14 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1978 | 53 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1978 | 34 | 0.000 |
Why?
|
| Sex Chromosomes | 1 | 1978 | 57 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1980 | 255 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1978 | 44 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1980 | 668 | 0.000 |
Why?
|
| Quinacrine Mustard | 1 | 1976 | 2 | 0.000 |
Why?
|
| Chromosomes | 1 | 1976 | 97 | 0.000 |
Why?
|
| Macrophages | 1 | 1975 | 571 | 0.000 |
Why?
|